What is Vaxcyte?
Headquartered in San Carlos, California, Vaxcyte operates at the forefront of biotechnology, focusing on the development of superior, novel vaccines. By leveraging advanced scientific methodologies, the company aims to mitigate the impact of deadly infectious diseases on a global scale. Its market position is defined by a rigorous approach to clinical development and a strategic focus on high-impact therapeutic areas, positioning it as a critical player in the modern healthcare landscape.
How much funding has Vaxcyte raised?
Vaxcyte has raised a total of $1.1B across 7 funding rounds:
Series A
$22M
Other Financing Round
$4M
Series B
$60M
Series C
$85M
Series D
$110M
Stock Offering
$100M
Share Placement
$750M
Series A (2015): $22M with participation from Longitude Capital, Roche, CTI Life Sciences Fund, and Abingworth
Other Financing Round (2017): $4M led by Abingworth, CTI Life Sciences Fund, Longitude Capital, and Roche
Series B (2017): $60M supported by Abingworth, Frazier Healthcare Partners, Longitude Capital, Roche, CTI Life Sciences Fund, and Pivotal Bioventure Partners
Series C (2018): $85M, investors not publicly disclosed
Series D (2020): $110M backed by Janus Henderson Investors, Longitude Capital, Roche, RA Capital Management , LLC, Abingworth LLP, Pivotal Bioventure Partners, Texas Pacific Group, Medixc, Foresite Capital, Frazier Health Care Partners, and CTI Life Sciences
Stock Issuance/Offering (2022): $100M, investors not publicly disclosed
Share Placement (2024): $750M, investors not publicly disclosed
Key Investors in Vaxcyte
Abingworth
A leading transatlantic life sciences investment firm that transforms cutting-edge science into novel medicines by providing capital and expertise to top-tier management teams.
CTI Life Sciences Fund
A prominent Canadian biotech venture capital firm focused on catalyzing innovative assets into scalable companies with a focus on long-term value creation.
Longitude Capital
A healthcare-focused venture capital firm that invests in biotechnology and medical technology, pairing sector expertise with flexible capital to help innovators scale.
What's next for Vaxcyte?
With the recent influx of capital, Vaxcyte is well-positioned to accelerate its clinical development programs and expand its research capabilities. The company's strategic roadmap likely involves advancing its lead candidates through late-stage clinical trials while simultaneously exploring new therapeutic modalities. As it transitions into a more mature phase of its lifecycle, the focus will remain on achieving regulatory milestones and scaling its manufacturing processes to meet global demand, ensuring that its innovative solutions reach the populations that need them most.
See full Vaxcyte company page
